Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Down 7.8% in December

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,377,300 shares, a decrease of 7.8% from the December 15th total of 1,494,600 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 13,773.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

BIOVF opened at $28.30 on Monday. Swedish Orphan Biovitrum AB has a one year low of $22.87 and a one year high of $32.25. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49. The business has a 50 day simple moving average of $28.41 and a two-hundred day simple moving average of $28.42. The firm has a market capitalization of $10.07 billion, a price-to-earnings ratio of 47.97 and a beta of 0.51.

Analyst Ratings Changes

Separately, Barclays upgraded shares of Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research report on Wednesday, January 8th.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.